Activities per year
- 4 results
Search results
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
Human relevant models for drug research and development
Fien Meeus (Speaker), Robin Maximilian Awad (Contributor), Nick Devoogdt (Contributor), Sandra Tuyaerts (Contributor), Cleo Goyvaerts (Contributor), Yannick De Vlaeminck (Contributor), Bart Neyns (Contributor) & Karine Breckpot (Contributor)
8 Oct 2021Activity: Talk or presentation › Talk or presentation at a workshop/seminar
-
Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): a multi-cohort adaptive phase I clinical trial
Julia Katharina Schwarze (Speaker), Wietse Geens (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), Anne-Marie Van Binst (Contributor), Hendrik Everaert (Contributor), Laura Seynaeve (Contributor), Alex Michotte (Contributor), Michaël Bruneau (Contributor), I VAN RIET (Contributor), Sandra Tuyaerts (Contributor), Johnny Duerinck (Contributor) & Bart Neyns (Contributor)
16 Sep 2021 → 21 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Presenter), Jens Tijtgat (Contributor), Gil Awada (Contributor), Louise Cras (Contributor), Inès Dufait (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor) & Bart Neyns (Contributor)
17 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference